SGLT2 Inhibitors for Primary Prevention of Cardiovascular Events

Journal of Diabetes - United States
doi 10.1111/1753-0407.13004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Aspirin for Primary Prevention of Cardiovascular Events

Journal of General Internal Medicine
Internal Medicine
1998English

SGLT2 Inhibitors

2020English

Statins for Primary Prevention of Cardiovascular Disease

British Medical Journal
Medicine
2019English

Cardiovascular Risk Prediction for Primary Prevention

Prescriber
Pharmacology
2019English

Primary Prevention of Cardiovascular Diseases

Scandinavian Journal of Primary Health Care
EnvironmentalPublic HealthOccupational Health
2003English

Correction To: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence Into Practice

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

SGLT2 Inhibitors: Mind the Gap

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View

2020English

Risk Scoring for the Primary Prevention of Cardiovascular Disease

2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy